Background The COVID-19 outbreak challenges the Spanish health system since March 2020. Some available therapies (antimalarials, antivirals, biological agents) were grounded on clinical case observations or basic science data. The aim of this study is to describe the characteristics and impact of different therapies on clinical outcomes in a cohort of severe COVID-19 patients. Methods In this retrospective, single-center, observational study, we collected sequential data on adult patients admitted to Hospital Universitario Quironsalud Madrid. Eligible patients should have a microbiological (positive test on RT-PCR assay from a nasal swab) or an epidemiological diagnosis of severe COVID-19. Demographic, baseline comorbidities, laboratory data, clinical outcomes, and treatments were compared between survivors and non-survivors. We carried out univariate and multivariate logistic regression models to assess potential risk factors for in-hospital mortality. Findings From March 10th to April 15th, 2020, 607 patients were included. Median age was 69 years [interquartile range, {IQR} 22; 65% male). The most common comorbidities were hypertension (276 [46·94%]), diabetes (95 [16·16%]), chronic cardiac (133 [22·62%]) and respiratory (114 [19·39%]) diseases. 141 patients (23·2%) died. In the multivariate model the risk of death increased with older age (odds ratio, for every year of age, 1·15, [95% CI 1·11 - 1·2]), tocilizumab therapy (2·4, [1·13 - 5·11]), C-reactive protein at admission (1·07, per 10 mg/L, [1·04 - 1·10]), d -dimer > 2·5 μg/mL (1·99, [1·03 - 3·86]), diabetes mellitus (2·61, [1·19 - 5·73]), and the PaO 2 /FiO 2 at admission (0·99, per every 1 mmHg, [0·98 - 0·99]). Among the prescribed therapies (tocilizumab, glucocorticoids, lopinavir/ritonavir, hydroxychloroquine, cyclosporine), only cyclosporine was associated with a significant decrease in mortality (0·24, [0·12 - 0·46]; p <0·001). Interpretation In a real-clinical setting, inhibition of the calcineurin inflammatory pathway, NF-κΒ, could reduce the hyperinflammatory phase in COVID-19. Our findings might entail relevant implications for the therapy of this disease and could boost the design of new clinical trials among subjects affected by severe COVID-19. Funding Hospital Universitario Quironsalud Madrid. Own fundings for COVID-19 research.

(1) Multiple in vitro studies reported insufficient accuracy of intraoral scanners (IOSs) for complete-arch multiple implant impression. The aim of the study is to analyze the precision of three IOSs, PIC dental (Pic dental, Iditec North West SL), TRIOS 3 (3Shape), and True Definition (Midmark Corporation) and the influence of several factors in the edentulous complete maxillary and mandibular arch. (2) A fully edentulous patient with eight implants in the maxillary and in the mandibular jaw was selected. Five impressions were taken per system and arch. A suprastructure was designed on each digital working cast. The precision was analyzed comparing each of the 28 distances and seven relative angulations of the abutments of all the designed suprastructures. The descriptive statistics, the Student’s t-test, and the ANOVA test were used to analyze the data (α = 0.05). (3) Significant differences were observed when comparing the IOSs in some of the distances and angulations. (4) The increase in the distance between implants affected the precision of T and TD but not the PIC system. The type of arch did not affect the PIC precision, but the T and TD systems performed worse in the mandibular arch. The system with the best precision was the PIC, followed by TD, and then T.

No abstract

No abstract

No abstract